RESUMEN
This comprehensive review delves into the evolving field of neurointervention for intracranial aneurysms, exploring the critical adjunct of Dual Antiplatelet Therapy (DAPT) to endovascular coiling, stent-assisted coiling (SAC), flow-diversion stents, and flow-disruption (intrasaccular) devices. Despite growing evidence supporting the success of DAPT in reducing thromboembolic events, the lack of consensus on optimal regimens, doses, and duration is evident. Factors contributing to this variability include genetic polymorphisms affecting treatment response and ongoing debates regarding the clinical significance of hemorrhagic complications associated with DAPT. This review analyzes pre- and post-procedural antiplatelet usage across various interventions. The imperative lies in ongoing research to define optimal DAPT durations, ensuring a nuanced approach to the delicate balance between thrombosis and hemorrhage in intracranial aneurysm management.
Asunto(s)
Procedimientos Endovasculares , Aneurisma Intracraneal , Inhibidores de Agregación Plaquetaria , Humanos , Aneurisma Intracraneal/cirugía , Aneurisma Intracraneal/tratamiento farmacológico , Procedimientos Endovasculares/métodos , Inhibidores de Agregación Plaquetaria/uso terapéutico , Inhibidores de Agregación Plaquetaria/administración & dosificación , Terapia Antiplaquetaria Doble/métodos , Consenso , StentsRESUMEN
BACKGROUND: The use of antithrombotic medication following acute flow diversion for a ruptured intracranial aneurysm (IA) is challenging with no current guidelines. We investigated the incidence of treatment-related complications and patient outcomes after flow diversion for a ruptured IA before and after the implementation of a standardized antithrombotic medication protocol. METHODS: We conducted a single-center retrospective study including consecutive patients treated for acutely ruptured IAs with flow diversion during 2015-2023. We divided the patients into two groups: those treated before the implementation of the protocol (pre-protocol) and those treated after the implementation of the protocol (post-protocol). The primary outcomes were hemorrhagic and ischemic complications. A secondary outcome was clinical outcome using the modified Ranking Scale (mRS). RESULTS: Totally 39 patients with 40 ruptured IAs were treated with flow diversion (69% pre-protocol, 31% post-protocol). The patient mean age was 55 years, 62% were female, 63% of aneurysms were in the posterior circulation, 92% of aneurysms were non-saccular, and 44% were in poor grade on admission. Treatment differences included the use of glycoprotein IIb/IIIa inhibitors (pre-group 48% vs. post-group 100%), and the use of early dual antiplatelets (pre-group 44% vs. 92% post-group). The incidence of ischemic complications was 37% and 42% and the incidence of hemorrhagic complications was 30% and 33% in the pre- and post-groups, respectively, with no between-group differences. There were three (11%) aneurysm re-ruptures in the pre-group and none in the post-group. There were no differences in mortality or mRS 0-2 between the groups at 6 months. CONCLUSION: We found no major differences in the incidence of ischemic or hemorrhagic complications after the implementation of a standardized antithrombotic protocol for acute flow diversion for ruptured IAs. There is an urgent need for more evidence-based guidelines to optimize antithrombotic treatment after flow diversion in the setting of subarachnoid hemorrhage.
Asunto(s)
Aneurisma Roto , Embolización Terapéutica , Procedimientos Endovasculares , Aneurisma Intracraneal , Humanos , Femenino , Persona de Mediana Edad , Masculino , Aneurisma Intracraneal/tratamiento farmacológico , Aneurisma Intracraneal/cirugía , Aneurisma Intracraneal/etiología , Fibrinolíticos/uso terapéutico , Estudios Retrospectivos , Resultado del Tratamiento , Procedimientos Endovasculares/métodos , Aneurisma Roto/tratamiento farmacológico , Aneurisma Roto/cirugía , Aneurisma Roto/etiología , Embolización Terapéutica/métodos , Protocolos Clínicos , StentsRESUMEN
OBJECTIVES: Heparin-induced thrombocytopenia is a known complication of heparin exposure with potentially life-threatening sequelae. Direct thrombin inhibitors can be substituted for heparin in patients with heparin-induced thrombocytopenia that require anticoagulation. However, the use of direct thrombin inhibitors as a substitute for heparin has not been widely reported in the neuroendovascular literature. MATERIALS AND METHODS: Here we report the first use of the direct thrombin inhibitor bivalirudin in a neuroendovascular procedure as a substitute for heparin in a patient with a ruptured pseudoaneurysm and heparin-induced thrombocytopenia, and review the literature on the use of bivalirudin and argatroban for such patients. RESULTS: Bivalirudin was safely and effectively used in the case reported, with no thrombotic or hemorrhagic complications. Our literature review revealed a paucity of studies on the use of heparin alternatives, including bivalirudin, in neuroendovascular procedures in patients with heparin-induced thrombocytopenia. CONCLUSIONS: Heparin-induced thrombocytopenia is an important iatrogenic disease process in patients undergoing neuroendovascular procedures, and developing protocols to diagnose and manage heparin-induced thrombocytopenia is important for healthcare systems. While further research needs to be done to establish the full range of anticoagulation options to substitute for heparin, our case indicates bivalirudin as a potential candidate.
Asunto(s)
Anticoagulantes , Antitrombinas , Heparina , Hirudinas , Fragmentos de Péptidos , Proteínas Recombinantes , Trombocitopenia , Humanos , Masculino , Persona de Mediana Edad , Aneurisma Falso/cirugía , Aneurisma Falso/tratamiento farmacológico , Aneurisma Roto/cirugía , Aneurisma Roto/diagnóstico por imagen , Anticoagulantes/efectos adversos , Antitrombinas/efectos adversos , Antitrombinas/uso terapéutico , Sustitución de Medicamentos , Procedimientos Endovasculares/efectos adversos , Heparina/efectos adversos , Aneurisma Intracraneal/cirugía , Aneurisma Intracraneal/tratamiento farmacológico , Fragmentos de Péptidos/uso terapéutico , Fragmentos de Péptidos/efectos adversos , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Proteínas Recombinantes/administración & dosificación , Trombocitopenia/inducido químicamente , Trombocitopenia/diagnóstico , Trombocitopenia/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Intracranial aneurysms (IAs) are rare vascular lesions that are more frequently found in women. The pathophysiology behind the formation and growth of IAs is complex. Hence, to date, no single pharmacological option exists to treat them. Animal models, especially mouse models, represent a valuable tool to explore such complex scientific questions. Genetic modification in a mouse model of IAs, including deletion or overexpression of a particular gene, provides an excellent means for examining basic mechanisms behind disease pathophysiology and developing novel pharmacological approaches. All existing animal models need some pharmacological treatments, surgical interventions, or both to develop IAs, which is different from the spontaneous and natural development of aneurysms under the influence of the classical risk factors. The benefit of such animal models is the development of IAs in a limited time. However, clinical translation of the results is often challenging because of the artificial course of IA development and growth. Here, we summarize the continuous improvement in mouse models of IAs. Moreover, we discuss the pros and cons of existing mouse models of IAs and highlight the main translational roadblocks and how to improve them to increase the success of translational IA research.
Asunto(s)
Aneurisma Intracraneal , Ratones , Animales , Humanos , Femenino , Aneurisma Intracraneal/tratamiento farmacológico , Aneurisma Intracraneal/genética , Investigación Biomédica Traslacional , Factores de Riesgo , Modelos Animales de EnfermedadRESUMEN
INTRODUCTION: Intracranial aneurysm (IA) is a common cerebrovascular disease. Considering the risks and benefits of surgery, a significant proportion of patients with unruptured IA (UIA) choose conservative observation. Previous studies suggest that inflammation of aneurysm wall is a high-risk factor of rupture. Dimethyl fumarate (DMF) acts as an anti-inflammatory agent by activating nuclear factor erythroid 2-related factor 2 (Nrf2) and other pathways. Animal experiments found DMF reduces the formation and rupture of IAs. In this study, DMF will be evaluated for its ability to reduce inflammation of the aneurysm wall in high-resolution vessel wall imaging. METHODS AND ANALYSIS: This is a multi-centre, randomised, controlled, double-blind clinical trial. Three hospitals will enrol a total of 60 patients who have UIA with enhanced wall. Participants will be assigned randomly in a 1:1 proportion, taking either 240 mg DMF or placebo orally every day for 6 months. As the main result, aneurysm wall enhancement will be measured by the signal intensity after 6 months of DMF treatment. Secondary endpoints include morphological changes of aneurysms and factors associated with inflammation. This study will provide prospective data on the reduction of UIA wall inflammation by DMF. ETHICS AND DISSEMINATION: This study has been approved by Medical Ethics Committee of the Beijing Tiantan Hospital, Capital Medical University (approval no: KY2022-064-02). We plan to disseminate our research findings through peer-reviewed journal publication and relevant academic conferences. TRIAL REGISTRATION NUMBER: NCT05959759.
Asunto(s)
Dimetilfumarato , Aneurisma Intracraneal , Humanos , Dimetilfumarato/uso terapéutico , Aneurisma Intracraneal/tratamiento farmacológico , Método Doble Ciego , Ensayos Clínicos Controlados Aleatorios como Asunto , Adulto , Masculino , Persona de Mediana Edad , Femenino , Antiinflamatorios/uso terapéuticoRESUMEN
BACKGROUND: Major perioperative complications of stent-assisted embolization treated for aneurysmal subarachnoid hemorrhage patients include the formation of thromboembolic events (TEs) and hemorrhagic events (HEs), for which antiplatelet protocols play a key role. METHODS: We conducted a single-center retrospective analysis to compare the differences between arteriovenous tirofiban administration with traditional oral dual antiplatelet therapy (DAPT). A total of 417 consecutive patients were enrolled. General clinical characteristics, as well as the perioperative ischemic and hemorrhagic events, were retracted in digital documents. Logistic regression was conducted to identify both risk and protective factors of perioperative TEs and HEs. RESULTS: Perioperative TEs occurred in 21 patients, with an overall perioperative TEs rate of approximately 5.04%; among these patients, the incidence of perioperative TEs in the tirofiban group was less than that in the DAPT group. Additionally, 66 patients developed perioperative HEs, with an incidence of approximately 15.83%; among these patients, the incidence of perioperative HEs was less than that in the DAPT group. No significant differences were seen between the two groups in terms of the mRS score at the time of discharge. CONCLUSION: This study indicated that an improved perioperative antiplatelet drug tirofiban was an independent protective factor for perioperative TEs in stent-assisted embolization of ruptured intracranial aneurysms, but it did not impart an elevated risk of perioperative HEs and had no significant effects on the near-term prognosis of the patients.
Asunto(s)
Aneurisma Intracraneal , Hemorragia Subaracnoidea , Humanos , Tirofibán/efectos adversos , Inhibidores de Agregación Plaquetaria , Hemorragia Subaracnoidea/terapia , Estudios Retrospectivos , Aneurisma Intracraneal/tratamiento farmacológico , Stents , Resultado del TratamientoRESUMEN
BACKGROUND: Antiplatelet therapy is pivotal in endovascular treatment for intracranial aneurysms. However, there is a lack of studies comparing ticagrelor to clopidogrel in patients with aneurysms undergoing endovascular therapy. Additionally, the existing literature lacks adequate sample size, significant subgrouping, and follow-up, making our study important to cover these gaps. METHODS: We searched 5 databases to collect all relevant studies. Categorical outcomes were pooled as relative risk (R.R.) with a 95% confidence interval (CI). In the single-arm meta-analysis, outcomes were pooled as proportions and their corresponding 95% CI. RESULTS: This comprehensive analysis of 18 studies involving 2,427 patients. For thromboembolic events, the pooled (R.R.) did not show significant differences, whether considering overall events. A similar pattern was observed for thromboembolic events stratified by aneurysmal rupture status, with no significant differences in overall events. Hemorrhagic events did not also exhibit significant differences in previously mentioned stratifications. Furthermore, there were no substantial differences in death and mRS (0-2) on discharge between Ticagrelor and Clopidogrel. Single-arm meta-analyses for Ticagrelor demonstrated low rates of thromboembolic events, hemorrhage, death, and favorable mRS scores, with associated confidence intervals (CIs). Main line of endovascular treatment did not significantly affect either thromboembolic or hemorrhagic outcomes with Ticagrelor and Clopidogrel. CONCLUSIONS: We found no significant differences in key outcomes like thromboembolic events, hemorrhagic events, mortality rates, and favorable mRS (0-2) upon discharge in the studied patients between Ticagrelor and Clopidogrel. Moreover, the single-arm meta-analysis for Ticagrelor revealed low rates of thromboembolic events, hemorrhage, mortality, and high rates of favorable mRS scores.
Asunto(s)
Procedimientos Endovasculares , Aneurisma Intracraneal , Humanos , Clopidogrel , Ticagrelor/uso terapéutico , Inhibidores de Agregación Plaquetaria , Aneurisma Intracraneal/tratamiento farmacológico , Aneurisma Intracraneal/cirugía , Hemorragia/inducido químicamente , Resultado del TratamientoRESUMEN
Relato de caso de neurofibromatose tipo I associada a doença oclusiva extensa do sistema carotídeo em sua porçao intracraniana e aneurisma fusiforme de circulaçao posterior. O paciente, de 28 anos de idade e com diagnóstico de doença de von Recklinghausen, passou a apresentar episódios de síncope, crises parciais complexas e declínio cognitivo. Após quadro agudo de cefaléia e sinais de irritaçao meníngea, com líquor hemorrágico, o paciente foi investigado com, TC de crânio, RNM e angiografia cerebral, sendo detectadas alteraçoes tipo moyamoya e dilataçao aneurismática de artéria cerebral posterior. Apresentamos os achados clínicos e radiológicos deste caso com poucos relatos similares na literatura médica, discutimos opçoes terapêuticas e reiteramos a inclusao de diagnósticos diferenciais raros em indivíduos que apresentem icto com menos de quarenta anos de idade.
Asunto(s)
Humanos , Masculino , Adulto , Aneurisma Intracraneal/complicaciones , Enfermedad de Moyamoya/complicaciones , Neurofibromatosis 1/complicaciones , Aneurisma Intracraneal/diagnóstico , Aneurisma Intracraneal/tratamiento farmacológico , Enfermedad de Moyamoya/diagnóstico , Enfermedad de Moyamoya/tratamiento farmacológico , Neurofibromatosis 1/diagnóstico , Neurofibromatosis 1/tratamiento farmacológicoRESUMEN
Relatamos o caso de uma doente de 36 anos que apresentou oclusão de um aneurisma fusiforme de artéria basilar associado a infarto pontino e dois episódios de hemorragia subaracnóide provavelmente devido a dissecção arterial. Ela também apresentava aneurismas fusiformes assintomáticos na artéria cerebral média direita e na artéria carótida interna esquerda. Ao longo de 5 anos, lesões compatíveis com displasia fibromuscular foram observadas na artéria vertebral direita, assim como oclusão da artéria vertebral esquerda. Esta combinação de lesões sugere que um mecanismo etiopatogênico comum tenha causado diferentes graus de comprometimento da camada média de artérias cervicocranianas.
Asunto(s)
Adulto , Femenino , Humanos , Arteriopatías Oclusivas/complicaciones , Enfermedades de las Arterias Carótidas/complicaciones , Aneurisma Intracraneal/complicaciones , Hemorragia Subaracnoidea/complicaciones , Ticlopidina/análogos & derivados , Arteriopatías Oclusivas/tratamiento farmacológico , Arteriopatías Oclusivas , Aspirina/uso terapéutico , Arteria Basilar , Arteria Carótida Interna , Angiografía Cerebral , Enfermedades de las Arterias Carótidas/tratamiento farmacológico , Enfermedades de las Arterias Carótidas , Aneurisma Intracraneal/tratamiento farmacológico , Aneurisma Intracraneal , Inhibidores de Agregación Plaquetaria/uso terapéutico , Hemorragia Subaracnoidea/tratamiento farmacológico , Hemorragia Subaracnoidea , Ticlopidina/uso terapéuticoRESUMEN
Os autores relatam o caso de um paciente com doença de Moya-Moya e aneurisma duplo da artéria basilar. Discutem os aspectos etiopatogênicos, o diagnóstico e a melhor forma de tratamento
Asunto(s)
Adulto , Humanos , Masculino , Aneurisma Intracraneal , Enfermedad de Moyamoya , Ácido Aminocaproico/uso terapéutico , Arteria Basilar , Angiografía Cerebral , Dexametasona/uso terapéutico , Aneurisma Intracraneal/tratamiento farmacológicoRESUMEN
Se presentan 10 pacientes que tenían más de un aneurisma intracraneal siendo el 90% del sexo femenino y la edad más frecuente la 5ta. década. El porcentaje de morbilidad fue de un 10% y el porcentaje de mortalidad de un 0%